Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,745 total articles

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Sep 8, 2026
Avery Klein
Press Releases

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Dyne Therapeutics announced that it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial studying z-basivarsen (DYNE-101) for treating Myotonic Dystrophy Type 1 (DM1) at two major upcoming neuromuscular medical meetings. The data include pooled dose group results versus a natural history cohort and updated safety informat…

DYN
Oportun Names Bill Franklin as Chief Financial Officer
Sep 8, 2026
Avery Klein
Press Releases

Oportun Names Bill Franklin as Chief Financial Officer

Oportun, a Nasdaq-listed financial services firm, announced the appointment of Bill Franklin as Chief Financial Officer. Franklin brings over 20 years of experience in financial leadership, including key roles at Discover Financial Services. His expertise is expected to drive Oportun's financial strategy and support its mission of empowering member…

OPRT
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Sep 8, 2026
Maya Rios
Press Releases

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

Clearmind Medicine Inc. announced Yale University's IRB approval to initiate patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100, a non-hallucinogenic psychedelic-derived drug candidate targeting Alcohol Use Disorder. This milestone follows positive safety results from Part A, allowing accelerated enrollment a…

CMND
GE Aerospace to Acquire Consolidated Precision Products (CPP), Expanding Mission-Critical Castings Capacity
Sep 8, 2026
Maya Rios
Press Releases

GE Aerospace to Acquire Consolidated Precision Products (CPP), Expanding Mission-Critical Castings Capacity

GE Aerospace has announced the acquisition of Consolidated Precision Products (CPP), a leading manufacturer of precision castings primarily serving commercial aerospace and defense markets. The $11.75 billion transaction is expected to be accretive to adjusted EPS and free cash flow in the first year, enhancing GE Aerospace's manufacturing capacity…

GE
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Sep 8, 2026
Ajmal Hussain
Press Releases

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay Ltd. reported positive results from a peer-reviewed pilot study on their Deep Transcranial Magnetic Stimulation (Deep TMS) technology treating patients with Major Depressive Disorder and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, alongside notable neurophysiologi…

BWAY
BioVie Announces Update to Parkinson’s Phase 3 Development Program
Sep 8, 2026
Nina Shah
Press Releases

BioVie Announces Update to Parkinson’s Phase 3 Development Program

BioVie Inc. announced progress in its Phase 3 clinical development program for bezisterim, a drug candidate for Parkinson's disease. The company is working with the FDA to finalize a trial design that includes motor symptom improvement as a primary endpoint and non-motor symptom improvement as a co-primary or secondary endpoint based on positive Ph…

BIVI
CervoMed to Participate in September Investor Conferences
Sep 8, 2026
Priya Menon
Press Releases

CervoMed to Participate in September Investor Conferences

CervoMed Inc., a clinical-stage biotech developing treatments for age-related brain disorders, announced management's participation in major September investor conferences. The company highlighted its lead drug candidate neflamapimod's progress, including a completed Phase 2b trial in dementia with Lewy bodies (DLB), discussions with the FDA on reg…

CRVO
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Sep 8, 2026
Leila Farooq
Press Releases

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

Artiva Biotherapeutics announced plans to initiate a Phase 3 registrational trial in refractory rheumatoid arthritis (RA) during the second half of 2026, alongside updated clinical data disclosures from their ongoing Phase 2a basket trial in RA, Sjögren disease, and systemic sclerosis. The company expects to present data from at least 20 RA patient…

ARTV
United Community Banks, Inc. Announces Completion of Strategic Initiatives That Simplify and Strengthen Balance Sheet; Increased Share Repurchase Authorization
Sep 8, 2026
Derek Hwang
Press Releases

United Community Banks, Inc. Announces Completion of Strategic Initiatives That Simplify and Strengthen Balance Sheet; Increased Share Repurchase Authorization

United Community Banks has finalized key strategic initiatives including the sale of Navitas Credit Corp., a significant repositioning of its investment securities portfolio to reduce interest rate risk and improve earnings, and an increased share repurchase authorization of $100 million through 2027. The company is focusing on organic loan growth,…

UCB
Edible Garden to Participate in ECRM’s Vitamin, Weight Management & Sports Nutrition Session, September 14–17, 2026
Sep 8, 2026
Ajmal Hussain
Press Releases

Edible Garden to Participate in ECRM’s Vitamin, Weight Management & Sports Nutrition Session, September 14–17, 2026

Edible Garden AG Incorporated announced its participation in ECRM's Vitamin, Weight Management & Sports Nutrition Session in September 2026, where it will highlight its Kick. Sports Nutrition line and expanding private-label ready-to-drink (RTD) products. The company aims to leverage these opportunities to expand distribution and scale its nutritio…

EDBL
Polar Power Reduces Pinnacle Bank Debt by $3 Million, from Approximately $4.7 Million to $1.667 Million; Expects Remaining Balance to Be Paid Down by End of September
Sep 8, 2026
Sofia Navarro
Press Releases

Polar Power Reduces Pinnacle Bank Debt by $3 Million, from Approximately $4.7 Million to $1.667 Million; Expects Remaining Balance to Be Paid Down by End of September

Polar Power, Inc. has successfully reduced its outstanding Pinnacle Bank debt by approximately $3 million, lowering the balance from $4.7 million to about $1.667 million as of September 2026. The company expects to fully repay the remaining balance by the end of September, substantially improving its financial flexibility and positioning for future…

POLA
Lantronix CEO to Participate in Upcoming Investor and Industry Events
Sep 8, 2026
Hana Yamamoto
Press Releases

Lantronix CEO to Participate in Upcoming Investor and Industry Events

Lantronix Inc., a leader in Edge AI and Industrial IoT solutions, announced that CEO Saleel Awsare will participate in several upcoming investor and industry events focused on government, defense technology, aerospace, and unmanned systems. These appearances aim to highlight Lantronix's capabilities in NDAA-compliant unmanned systems and critical i…

LTRX
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
Sep 8, 2026
Nina Shah
Press Releases

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

Zenas BioPharma announced a virtual investor event to discuss Obexelimab, its lead drug candidate for treating Immunoglobulin G4-Related Disease (IgG4-RD). The event will cover disease overview, treatment landscape, and the company's commercial strategies ahead of potential FDA approval. The FDA has accepted Zenas' Biologics License Application for…

ZBIO